Semaglutide mimics a hormone called GLP-1, which helps regulate appetite and reduce cravings
This study offers important strengths, including large sample sizes and real-world TriNetX data that enhance generalizability
In 2019 and 2020, a formulation of Semaglutide (brand name Rybelsus) was approved as a daily oral medication for treating diabetes, when used along with diet and exercise
Statistical analysis The data analyses were conducted using GraphPad Prism, version 8, developed by GraphPad Software in San Diego, CA, USA
You can contact Alpha Rejuvenation at tel:+19496421364 or [email protected] for more information
Compounding Safety Context Compounded GLP-1 medications are not FDA-approved products